A method of production of a tissue sealing patch is disclosed. The method comprises applying a vacuum to a heated work surface; applying a solution of a biocompatible polyurethane polymer to the work surface and spreading it over the work surface with a polymer blade; evaporating the solvent; heating the work surface above the softening temperature of the polymer; spreading powdered tissue sealant material over the polymer film; incorporating the tissue sealant material to a depth of 20-60 μm in the film by pressing on a release sheet placed over the powder and polymer film; removing the release sheet from the adhesive patch material; releasing the vacuum; cooling said work surface; and removing the adhesive patch material from said work surface. The biocompatible polymer preferably comprises PEG-caprolactone-lactic acid units connected by urethane linkages, the PEG having a molecular weight of 3000-3500 amu, and a CL:LA:PEG ratio of 34:2:1.

A method of production of a tissue sealing patch is disclosed. The method comprises applying a vacuum to a heated work surface; applying a solution of a biocompatible polyurethane polymer to the work surface and spreading it over the work surface with a polymer blade; evaporating the solvent; heating the work surface above the softening temperature of the polymer; spreading powdered tissue sealant material over the polymer film; incorporating the tissue sealant material to a depth of 20-60 μm in the film by pressing on a release sheet placed over the powder and polymer film; removing the release sheet from the adhesive patch material; releasing the vacuum; cooling said work surface; and removing the adhesive patch material from said work surface. The biocompatible polymer preferably comprises PEG-caprolactone-lactic acid units connected by urethane linkages, the PEG having a molecular weight of 3000-3500 amu, and a CL:LA:PEG ratio of 34:2:1.

Disclosed herein is an anti-adhesion kit comprised of: (i) a fibrinogen solution component comprising: fibrinogen at a concentration of about 5 to 25 mg/ml; and free calcium ions at a concentration ranging from 0.1 μM to 1 mM; and (ii) a thrombin component containing thrombin. Further disclosed is an anti-adhesion kit comprised of: (i) a fibrinogen solution component containing fibrinogen at a concentration of 8% to 25% of total protein by weight, and optionally free calcium ions at a concentration ranging from 0.1 μM to 1 mM; wherein a total protein concentration ranges from about 80 to 120 mg/ml; and (ii) a thrombin component containing thrombin. Methods of using the kits e.g., to provide anti-adhesion curable compositions are also disclosed.

Disclosed herein is an anti-adhesion kit comprised of: (i) a fibrinogen solution component comprising: fibrinogen at a concentration of about 5 to 25 mg/ml; and free calcium ions at a concentration ranging from 0.1 μM to 1 mM; and (ii) a thrombin component containing thrombin. Further disclosed is an anti-adhesion kit comprised of: (i) a fibrinogen solution component containing fibrinogen at a concentration of 8% to 25% of total protein by weight, and optionally free calcium ions at a concentration ranging from 0.1 μM to 1 mM; wherein a total protein concentration ranges from about 80 to 120 mg/ml; and (ii) a thrombin component containing thrombin. Methods of using the kits e.g., to provide anti-adhesion curable compositions are also disclosed.

An example medical device includes a vascular device, such as a catheter, and an anti-thrombogenic coating on a surface of the vascular device, such as a surface likely to contact blood. The anti-thrombogenic coating includes one or more peptides configured to interact with fibrinogen in the blood, such as a first type of peptides configured to bind to fibrinogen a second type of peptides configured to inhibit conversion of fibrinogen to fibrin. The anti-thrombogenic coating also includes a polymer, such as a hydrocolloid polymer, a tunable polyethylene glycol (PEG), or other controlled release polymer configured to control release of the one or more peptides and maintain a concentration of the peptides at the surface of the anti-thrombogenic coating above a minimum inhibitory concentration, thereby inhibiting thrombin formation on the intravascular medical device.

The present disclosure relates to the technical field of biomedicine, in particular to use of advanced platelet-rich fibrin (A-PRF) in preparing a medicament for the treatment of diabetic foot ulcer. The A-PRF provided by the present disclosure has a loose reticular fibrin structure, can be rich in more platelets and leukocytes, can release a plurality of growth factors and cytokines more persistently, and is more beneficial to tissue regeneration and wound repair. The medicament prepared from the A-PRF shortens the healing period of the diabetic foot ulcer, improves the healing rate, and has an excellent treatment effect and high safety.

This document provides methods and materials for performing retinal pigment epithelium transplantation. For example, methods and materials for using fibrin supports for retinal pigment epithelium transplantation are provided.

Recombinant Fibrinogen C Domain Containing 1 (rFibcd1) proteins and methods for using the same in the treatment of muscle atrophy are provided as are vectors, host cells, pharmaceutical compositions and modified RNA molecules encoding the rFibcd1 proteins.

The present invention relates to a product and method of using albumin nanoparticles for augmenting the function or effectiveness of stem cells or precursor cells in vivo. An albumin nanoparticle suspension containing submicron albumin spheres is prepared, with the albumin spheres being capable of augmenting a function and effectiveness of stem cells or precursor cells in vivo. A predetermined amount of the albumin nanoparticle suspension is administered to a patient before or after an onset of at least one condition. The condition is one that can benefit from a healing effect of the stem cells or precursor cells. A function of the stem cells or precursor cells are augmented or improved by the albumin spheres to repair cellular or tissue damage, resulting in decreasing mortality or morbidity of the patient. The albumin spheres can be bound with fibrinogen molecules in vitro or in vivo.

A method of treating radiation-induced skin toxicity or skin ulcers with nanoparticles after exposure to ionizing radiation and after an onset of radiation-induced skin toxicity or a radiation-induced skin ulcer by administering intravenously a suspension including fibrinogen-coated albumin nanospheres to a patient. A concentration of the suspension being sufficient to at least one of promote healing of the skin toxicity or reduce a size of the skin ulcer. The suspension can include fibrinogen-coated albumin nanospheres, sorbitol and/or caprylate. The suspension can be utilized for treating a patient to reduce an amount of blood loss in an organ of the patient or for treating a patient to mobilize stem cells or progenitor cells to accelerate healing of a wound.